U.S. drug giant Merck is paying $ 300 million in a deal possibly worth more than $ 5 billion to partner Eisai in an effort to boost its
star cancer immunotherapy treatment Keytruda, which could match up well in a combination with Eisai's Lenvima.
Speaking of checkpoint inhibitor drugs... Merck's star
cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.
The FDA has approved a four - week dosing schedule for Bristol - Myers Squibb's
cancer immunotherapy treatment Opdivo, doubling the current two - week schedule for a variety of cancers.
«Insights derived from these data will be critical to improving the effectiveness of
current cancer immunotherapy treatments and developing new immune - based treatment strategies,» said Justin Guinney, Ph.D., principal investigator, director of computational oncology and bioinformatics at Sage Bionetworks.
Biomedical researchers have developed a technique that uses a patch embedded with microneedles — like the patch pictured here — to
deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer.
Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver
cancer immunotherapy treatment directly to the site of melanoma skin cancer.
«Oncolytic viruses are the next wave of
promising cancer immunotherapy treatments,» says Dr. Steven Powell, a medical oncologist with the Sanford Cancer Center in Sioux Falls, S.D., who collaborated with Vyriad on the development of this clinical trial.
The Cancer Research Institute (CRI) and the Focused Ultrasound Foundation (FUSF) established a partnership in 2017 with the goal of advancing the development of new focused ultrasound (FUS) and
cancer immunotherapy treatments.